全文获取类型
收费全文 | 798篇 |
免费 | 44篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 9篇 |
妇产科学 | 11篇 |
基础医学 | 66篇 |
口腔科学 | 10篇 |
临床医学 | 93篇 |
内科学 | 138篇 |
皮肤病学 | 4篇 |
神经病学 | 78篇 |
特种医学 | 51篇 |
外科学 | 82篇 |
综合类 | 32篇 |
预防医学 | 31篇 |
眼科学 | 28篇 |
药学 | 118篇 |
中国医学 | 2篇 |
肿瘤学 | 76篇 |
出版年
2023年 | 3篇 |
2022年 | 22篇 |
2021年 | 30篇 |
2020年 | 12篇 |
2019年 | 29篇 |
2018年 | 21篇 |
2017年 | 16篇 |
2016年 | 16篇 |
2015年 | 21篇 |
2014年 | 23篇 |
2013年 | 42篇 |
2012年 | 63篇 |
2011年 | 61篇 |
2010年 | 35篇 |
2009年 | 35篇 |
2008年 | 57篇 |
2007年 | 54篇 |
2006年 | 47篇 |
2005年 | 52篇 |
2004年 | 44篇 |
2003年 | 43篇 |
2002年 | 29篇 |
2001年 | 19篇 |
2000年 | 5篇 |
1999年 | 13篇 |
1998年 | 7篇 |
1997年 | 7篇 |
1996年 | 6篇 |
1995年 | 4篇 |
1994年 | 5篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1991年 | 4篇 |
1990年 | 8篇 |
1989年 | 2篇 |
1979年 | 2篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1971年 | 1篇 |
1968年 | 1篇 |
排序方式: 共有843条查询结果,搜索用时 31 毫秒
21.
SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway 总被引:9,自引:0,他引:9
下载免费PDF全文
![点击此处可从《Proceedings of the National Academy of Sciences of the United States of America》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Woodford-Richens KL Rowan AJ Gorman P Halford S Bicknell DC Wasan HS Roylance RR Bodmer WF Tomlinson IP 《Proceedings of the National Academy of Sciences of the United States of America》2001,98(17):9719-9723
Loss of chromosome 18q21 is well documented in colorectal cancer, and it has been suggested that this loss targets the DCC, DPC4/SMAD4, and SMAD2 genes. Recently, the importance of SMAD4, a downstream regulator in the TGF-beta signaling pathway, in colorectal cancer has been highlighted, although the frequency of SMAD4 mutations appears much lower than that of 18q21 loss. We set out to investigate allele loss, mutations, protein expression, and cytogenetics of chromosome 18 copy number in a collection of 44 colorectal cancer cell lines of known status with respect to microsatellite instability (MSI). Fourteen of thirty-two MSI(-) lines showed loss of SMAD4 protein expression; usually, one allele was lost and the other was mutated in one of a number of ways, including deletions of various sizes, splice site changes, and missense and nonsense point mutations (although no frameshifts). Of the 18 MSI(-) cancers with retained SMAD4 expression, four harbored missense mutations in the 3' part of the gene and showed allele loss. The remaining 14 MSI(-) lines had no detectable SMAD4 mutation, but all showed allele loss at SMAD4 and/or DCC. SMAD4 mutations can therefore account for about 50-60% of the 18q21 allele loss in colorectal cancer. No MSI(+) cancer showed loss of SMAD4 protein or SMAD4 mutation, and very few had allelic loss at SMAD4 or DCC, although many of these MSI(+) lines did carry TGFBIIR changes. Although SMAD4 mutations have been associated with late-stage or metastatic disease, our combined molecular and cytogenetic data best fit a model in which SMAD4 mutations occur before colorectal cancers become aneuploid/polyploid, but after the MSI(+) and MSI(-) pathways diverge. Thus, MSI(+) cancers may diverge first, followed by CIN(+) (chromosomal instability) cancers, leaving other cancers to follow a CIN(-)MSI(-) pathway. 相似文献
22.
23.
24.
Harpreet Singh Minhas Gagan Jain Chirantan Mangukia Mayank Goyal 《Indian heart journal》2014,66(5):539-542
We present a case of Tricuspid valve Aspergillus endocarditis with saddle shaped massive pulmonary embolism occurring in an immunocompetent host. The patient was managed uniquely by pulmonary endarterectomy (PEA) and combination antifungal chemotherapy with Liposomal amphotericin-B + caspofungin. 相似文献
25.
Amitava Banerjee Laura Pasea Sinduja Manohar Alvina G Lai Eade Hemingway Izaak Sofer Michail Katsoulis Harpreet Sood Andrew Morris Caroline Cake Natalie K Fitzpatrick Bryan Williams Spiros Denaxas Harry Hemingway and members of the Health Data Research UK COVID- Patient Public Involvement Engagement Panel 《Clinical medicine (London, England)》2021,21(6):e620
26.
Jane Wolstenholme Francesco Fusco Alastair M. Gray Joanna Moschandreas Pradeep S. Virdee Sharon Love Guy Van Hazel Peter Gibbs Harpreet S. Wasan Ricky A. Sharma 《International journal of cancer. Journal international du cancer》2020,147(4):1078-1085
Selective internal radiotherapy (SIRT) is a liver-directed treatment involving the injection of yttrium-90 microspheres into the blood supply of liver tumours. There are very few studies assessing health-related quality of life (HRQOL) in patients treated with SIRT. Patients with liver metastases from colorectal cancer (CRC) were randomised in the FOXFIRE (FFr; ISRCTN83867919), SIRFLOX (SF; NCT00724503) and FOXFIRE-Global (FFrG; NCT01721954) trials of first-line oxaliplatin–fluorouracil (FOLFOX) chemotherapy combined with SIRT versus FOLFOX alone. HRQOL was assessed using the three-level EQ-5D, European Organisation for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) and EORTC Colorectal Liver Metastases cancer module (EORTC QLQ-LMC21) at baseline, ≤3 months, 6 months, 12 months and annually thereafter from randomisation, and at disease progression. Analyses were conducted on an intention-to-treat basis. In total, 554 patients were randomised to SIRT + FOLFOX and 549 patients to FOLFOX alone. HRQOL was statistically significant lower in SIRT + FOLFOX patients ≤3 months after SIRT administration in all three instruments, particularly global health, physical and role functioning and symptoms of fatigue, nausea/vomiting and appetite loss. By accepted thresholds, these differences were deemed not clinically important. Differences between SIRT + FOLFOX and FOLFOX alone over the 2-year follow up and at disease progression were also not clinically important. Although there is some decrease in HRQOL for up to 3 months following SIRT, the addition of SIRT to FOLFOX chemotherapy does not change HRQOL to a clinically important degree in metastatic CRC patients. 相似文献
27.
28.
29.
30.
This review article addresses the recently discovered finding that cholesteryl ester transfer protein (CETP) can facilitate the transfer of water-insoluble drugs between different lipoprotein subclasses. This protein, which is often referred to as lipid transfer protein I (LTP I), is involved in the lipid regulation of lipoproteins. It is responsible for the facilitated transfer of core lipoprotein lipids, cholesteryl ester and triglycerides, and approximately one-third of the coat lipoprotein lipid, phosphatidylcholine, between different plasma lipoproteins. The human body appears to recognize exogenous water-insoluble drugs as lipid-like particles, which suggests that these compounds may interact with lipoproteins just like endogenous plasma lipids, and thus their transfer between lipoproteins may be facilitated by plasma CETP. Patients with a variety of diseases (i.e. diabetes, cancer, AIDS) often exhibit hypo- and/or hypercholesterolemia and triglyceridemia, commonly referred to as dyslipidemias, which result in changes in their plasma lipoprotein-lipid composition and concentration. The interaction of water-insoluble drugs with these dyslipidemic lipoproteins may be responsible for the differences seen in the pharmacokinetics and pharmacodynamics of the drug within different diseased patient populations. It is possible that these differences may be linked to the ability of CETP to transfer these compounds from one lipoprotein to another. This review examines the current understanding of the relationship between CETP activity and the lipoprotein distribution of a number of compounds (e.g. amphotericin B and cyclosporine A). It further suggests that additional research will expand our understanding of the role of CETP to explain other functions in lipophilic drug distribution and metabolism. 相似文献